Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

267
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
267
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

2.3K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
2.3K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential Role of Polyphenols in Platelet Aggregation and Blood Coagulation.

Journal of cardiovascular development and disease·2026
Same author

Fibrin formation and lysis in hyperglycaemia - molecular and cellular drivers.

Current opinion in hematology·2026
Same author

Predicting trajectories of illness using RNA velocity of whole blood.

Nature communications·2026
Same author

Modulatory Effects of Polyphenols on Altered Leukocyte Functions in Thromboinflammation and Diabetes Mellitus.

International journal of molecular sciences·2026
Same author

Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 Diabetes.

JACC. Basic to translational science·2026
Same author

A Neutrophil-like Cell Model as Substitute for Human Neutrophils in NETs and Thrombosis Research.

Cells·2026
Same journal

Semisynthesis of Mycothiazole Analogs having Distinct Bioactivity.

ACS medicinal chemistry letters·2026
Same journal

Investigation on the Cytotoxicity of Hydroxycinnamic and Hydroxybenzoic Acid-Based Natural Antioxidant Conjugated Terpyridine Analogues toward Triple-Negative Breast Cancer.

ACS medicinal chemistry letters·2026
Same journal

Beyond Neddylation Inhibition: X‑ray Structures Reveal Carbonic Anhydrase Isoform Selectivity of Pevonedistat.

ACS medicinal chemistry letters·2026
Same journal

Structure-Guided Discovery of Selective Polo-Like Kinase 3 Inhibitors.

ACS medicinal chemistry letters·2026
Same journal

Controlling Neuroplasticity Across Scales: Constrained Serotonergic Agonists, Neuroplastogens, and Adaptive Neuromodulation.

ACS medicinal chemistry letters·2026
Same journal

Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in Cancer.

ACS medicinal chemistry letters·2026
See all related articles

Related Experiment Video

Updated: Oct 3, 2025

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

637

A Comparative Assessment Study of Known Small-molecule GPVI Modulators.

Holly Foster1,2, Clare Wilson2, Julia S Gauer2

  • 1School of Chemistry, University of Leeds, Leeds LS2 9JT, U.K.

ACS Medicinal Chemistry Letters
|February 18, 2022
PubMed
Summary
This summary is machine-generated.

Researchers assessed small-molecule antagonists for the GPVI receptor, a target for thrombosis treatment. Losartan and compound 5 demonstrated the most viability as GPVI modulators, offering potential for new antiplatelet therapies.

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.8K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.0K

Related Experiment Videos

Last Updated: Oct 3, 2025

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

637
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.8K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.0K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Background:

  • The glycoprotein VI (GPVI) platelet receptor is a validated target for antiplatelet therapy in thrombosis.
  • Existing small-molecule GPVI antagonists are often weakly potent and lack robust validation.
  • Previous studies faced challenges comparing efficacy due to donor variability in assays.

Purpose of the Study:

  • To conduct the first side-by-side assessment of reported small-molecule GPVI antagonists.
  • To characterize the functional activities and binding of these modulators.
  • To identify the most viable small-molecule GPVI modulators for further development.

Main Methods:

  • Functional assays: Flow cytometry, light transmission aggregometry, and electrical impedance aggregometry to assess platelet activation and aggregation.
  • Binding assays: Microscale thermophoresis (MST) and saturation transfer difference (STD) NMR to confirm GPVI binding.
  • Computational methods: Molecular modeling to predict potential binding interactions.

Main Results:

  • A comprehensive functional and binding characterization of multiple GPVI small-molecule modulators was performed.
  • Losartan and a specific compound, designated as compound 5, were identified as the most promising GPVI modulators among those tested.
  • Binding interactions were elucidated using biophysical techniques and molecular modeling.

Conclusions:

  • Losartan and compound 5 represent the most viable small-molecule GPVI modulators currently available.
  • This study provides a critical comparative analysis, addressing limitations of previous research.
  • The findings support the continued investigation of these compounds for antiplatelet therapy.